Two-Drug combo may boost outcomes in High-Risk PAH patients
NCT ID NCT07245680
First seen Jan 06, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This study looks at people newly diagnosed with pulmonary arterial hypertension (PAH) who also have at least two heart-related conditions. It compares starting treatment with two oral medications (tadalafil and ambrisentan) versus just one. The goal is to see if the combination helps more patients reach a lower risk level after 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Bicêtre -Service de pneumologie et soins intensifs respiratoires
Le Kremlin-Bicêtre, 94270, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.